Search research articles
Contact Us
Filters
Showing results (141-150 of 162) with videos related to
Page
of 17
Sort By:
Breast (Edinburgh, Scotland)
|
April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
Francesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.
Nature Communications
|
June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
Davide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Cancers
|
January 11, 2024
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
Marina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial
Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.
Breast (Edinburgh, Scotland)
|
January 31, 2026
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, et al.
Nature Medicine
|
September 30, 2025
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Paolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, et al.
Oncotarget
|
August 31, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
Marina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Breast Care (Basel, Switzerland)
|
April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Marina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
Cancer Treatment Reviews
|
October 22, 2024
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project
Stefania Gori, Fiorenza De Rose, Antonella Ferro, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 162) with videos related to
Sort By:
Page
of 17
Breast (Edinburgh, Scotland)
|
April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
Francesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.
Nature Communications
|
June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
Davide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Cancers
|
January 11, 2024
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
Marina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial
Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.
Breast (Edinburgh, Scotland)
|
January 31, 2026
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, et al.
Nature Medicine
|
September 30, 2025
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Paolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, et al.
Oncotarget
|
August 31, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
Marina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Breast Care (Basel, Switzerland)
|
April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Marina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
Cancer Treatment Reviews
|
October 22, 2024
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project
Stefania Gori, Fiorenza De Rose, Antonella Ferro, et al.
Page
of 17